Rapid profiling of drug candidates

In the hunt for new medicines, any technique that expedites drug candidates into the clinic is a welcome advance. A team led by Hiroyuki Osada at the RIKEN Advanced Science Institute, Wako, recently developed a faster way to unravel the mode of action of experimental anticancer drugs, an essential step in the drug development pathway. The team—including RIKEN researchers Makoto Kawatani and Makoto Muroi—is now using this so-called ‘proteomic profiling’ technique to assess new drug leads, including a promising compound dubbed BNS-22. 

Read the whole article on Physorg

More from Physorg